Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 04, 2025 16:01 ET | Source: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAARDEN, the Netherlands and MIAMI, April 04, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
March 31, 2025 08:00 ET | Source: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

NAARDEN, the Netherlands and MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
February 26, 2025 08:00 ET | Source: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

-- EMA submission expected in 2H25 by partner Menarini -- -- Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025 -- -- Phase 3 PREVAIL CVOT remains on track -- ...
February 25, 2025 08:00 ET | Source: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

NAARDEN, The Netherlands and MIAMI, Feb. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
February 07, 2025 16:01 ET | Source: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAARDEN, the Netherlands and MIAMI, Feb. 07, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
January 29, 2025 08:00 ET | Source: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference

NAARDEN, The Netherlands and MIAMI, Jan. 29, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
January 10, 2025 08:00 ET | Source: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities

-- Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025; expected to support global regulatory filings for obicetrapib, including EMA submission in 2H25 by our partner...
January 09, 2025 15:38 ET | Source: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAARDEN, the Netherlands and MIAMI, Jan. 09, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
December 13, 2024 17:16 ET | Source: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

NAARDEN, The Netherlands and MIAMI, Dec. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
December 11, 2024 21:37 ET | Source: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NAARDEN, the Netherlands and MIAMI, Dec. 11, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...